PARP1 and myelodysplastic syndrome: Encouragingly, the risk of secondary malignancies, such as acute myeloid leukemia or other myelodysplastic syndromes, appears to be relatively uncommon in patients treated with PARP inhibitors, indicating that PARP inhibitors can be used safely for longer‐term maintenance therapy [42].